O
ut-of-hospital cardiac arrest has a high incidence with ≈400 000 cases in the United States each year. 1 Between 20% and 40% of these patients achieve return of spontaneous circulation resulting in hospital admission. 2, 3 Although return of spontaneous circulation is strongly associated with survival, only 25% to 40% of admitted patients survive to hospital discharge. The most common cause of death for patients admitted after cardiac arrest is neurological injury. However, shock accounts for most deaths within the first 3 days. 4 Given these competing risks, the selection of candidates for advanced hemodynamic therapies should consider both neurological and hemodynamic prognosis.
Although the timing of coronary angiography following cardiac arrest without signs of ST-segment-elevation myocardial infarction remains controversial, there has been a dramatic rise in the use of mechanical circulatory support that can be deployed quickly and safely in the cardiac catheterization laboratory to support patients experiencing cardiac arrest. These devices include extracorporeal membrane oxygenation, Impella, and Tandem Heart. Multiple small observational studies have demonstrated that post-cardiac arrest shock can be effectively treated with these devices. 5, 6 However, the logistical and financial burdens of these advanced therapies, the risk of complications to the patient, and the absence of definitive randomized trials have led some clinicians to a nihilistic resistance to the use of these support technologies in patients after cardiac arrest. Wider adoption of hemodynamic support technologies will require accurate identification of neurologically viable patients likely to develop shock such that they would benefit from advanced hemodynamic support. To date, no such identification system exists.
In this issue of Circulation, Bascom et al 7 describe the development and validation of a simple scoring system for the prediction of refractory hemodynamic compromise for patients who survived to intensive care unit admission after outof-hospital cardiac arrest. The CREST score comprises the following factors: (1) known history of coronary artery disease; (2) nonshockable rhythm on presentation to emergency medical services; (3) left ventricular ejection fraction <30% on admission; (4) shock at the time of admission to the intensive care unit (including systolic blood pressure <90 mm Hg despite fluids, inotropes, pressors, and need for an intraaortic balloon pump); and (5) ischemic time >25 minutes (from time of arrest to return of spontaneous circulation). The primary outcome was a composite of death from repeat cardiopulmonary arrest, progressive refractory shock, refractory arrhythmia, or progressive lactic acidosis and multiorgan system failure as determined by the treating physician.
The CREST score attempts to predict refractory cardiovascular compromise in patients treated with current standards of practice. It is intended as an adjunct to neurological assessment to fully assess the patient's risk for the 2 primary causes of death after cardiac arrest. Higher CREST scores were associated with increased risk for the primary outcome of refractory cardiovascular compromise (50% risk for those with a score of 5). Although the primary outcome occurred in 19% of the derivation and validation cohorts evaluated by Bascom et al, multiple studies have shown improved survival when more advanced hemodynamic support options are used. 6 Therefore, the CREST score may be best used as an impetus to consider more aggressive hemodynamic support. It is important to note, however, that this hypothesis was not tested in the current study.
Ideally, the decision to escalate care would be made in concert with neurological prognostication such that only neurologically viable patients would be considered for advanced support. However, rapid neurological prognostication is difficult, particularly early in the patient's course. The American Heart Association 2015 guidelines for post-cardiac arrest care support the use of neurological examination findings no earlier than 72 hours after return to normothermia with a typical time for prognostication at 4 to 5 days. 8 Brain electroencephalograms are similarly best assessed at 72 hours after return to normothermia. Brain imaging, including marked reduction of the gray-to-white ratio on computed tomography performed within 2 hours of the cardiac arrest or restriction of diffusion on magnetic resonance imaging performed between days 2 and 6 after the cardiac arrest, may also be used to predict a poor neurological outcome. Bilateral absence of the N20 somatosensory evoked potential may be considered a predictor of poor outcome at 24 to 72 hours after return to normothermia. Unfortunately, no single test is accurate for neurological prognostication, and results are best assessed days into the hospital course. Therefore, the ultimate objective for advanced mechanical support programs, accurately identifying patients who are both neurologically viable and at risk of cardiovascular collapse, is not achievable at this time and requires further study and innovation.
The CREST score does not include patients with ST-segment-elevation myocardial infarction on ECG, because the recommended treatment pathway is more established in this population. It is interesting to note that these patients tend to have high survival rates (>70%). 9 Thus, excluding these patients is likely to provide a more accurate assessment of risk for the primary outcome by avoiding the dilutional effects of these patients with higher survival probability on the score. It may be interesting to apply a prognostic score to this population when considering advanced support, but the authors instead focus on patients without ST-segment elevation in an effort to focus on patients whose treatment pathway is less clear. Patients who had an in-hospital cardiac arrest were also excluded, but would likely confound the results because of the presence of multiple comorbid conditions. Patients with ongoing cardiopulmonary resuscitation and refractory cardiac arrest were also excluded from this data set. Whereas this population could technically be categorized as having shock, their expected mortality is substantially higher than that of the group included in this study. Even in this high-risk group, a significant benefit with advanced hemodynamic support may exist. 3, 6 Therefore, patients with ongoing cardiopulmonary resuscitation should be included in future prognostic scores if supported with advanced mechanical support. 6 The CREST score predicts refractory hemodynamic compromise on admission to the intensive care unit based on the data available in the International Cardiac Arrest Registry. Patients surviving to the emergency department but not to the intensive care unit were excluded from this study. Future versions of the CREST score will hopefully address patients in the emergency department where the CREST criteria could easily be implemented, including the completion of a bedside ECG. This is a time-critical period for advanced mechanical hemodynamic support, because the benefits of initiating this support are higher when delivered as early as possible. In addition, the logistic and patient safety issues associated with transport to the cardiac catheterization laboratory and the intensive care unit are best addressed with a cohesive plan established early in the emergency department. Other unstudied variables such as lactic acid, a marker of accrued hypoperfusion, 10, 11 or a clinical history of end-stage renal failure requiring hemodialysis 12 may also be readily accessible in the emergency department and may further enhance the prognostic capabilities of the score.
We should be cautious generalizing the CREST score to all patients who experience out-of-hospital cardiac arrest given our evolving understanding of resuscitation outcomes. Although patients presenting with shockable rhythms are the minority of all out-of-hospital cardiac arrest (25% to 30%), they represent >85% of all survivors, likely because of a high prevalence of reversible causes of arrest. 6, 13, 14 Acute contractile dysfunction, present for the first 3 to 5 days after prolonged cardiopulmonary resuscitation and resuscitation, appears to be mostly reversible. Early implementation of extracorporeal membrane oxygenation to support patients through those 3 to 5 days may lead to nearcomplete recovery of left ventricular function. 11 Thus, despite the resistance of clinicians to more invasive life support, post-cardiac arrest myocardial dysfunction appears treatable with hemodynamic and pulmonary support during postarrest shock and acute lung injury. 6, 11 Given the dramatic differences in survival rates between shockable and nonshockable rhythms, these groups should be differentiated in an effort to predict and identify viable patients. 15 In conclusion, we congratulate Bascom et al for this important effort to provide prognostication for cardiovascular death in postresuscitation patients by using the current standards of care. As we accrue data regarding the role of early implementation of new technologies to facilitate recovery for patients experiencing cardiac arrest, the development of accurate prognostic tools to differentiate the risks of poor neurological or hemodynamic outcomes may be the most important task in the near future. The field of cardiopulmonary resuscitation is facing rapid evolution with newly defined capabilities. However, many challenges lie ahead to appropriately provide these capabilities to improve outcomes, minimize complications, limit cost, and simplify implementation.
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